According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
Biomarkers have many potential applications in oncology including:
11
May, 2021
The Right Leadership and Technology Partnerships designed to deliver clinical solutions to cancer care management. Dr. Haince bring solid capabilities in clinical development and commercialization of cancer diagnostic tests in N. America, Accreditation and core lab management expertise, scientific…
READ MORE
6
Apr, 2021
Mikenomics | April 6, 2021 Earlier and faster cancer detection is the goal of research underway here in Alberta.With funding from the Spark Grants, The Metabolomics Innovation Centre (TMIC) based at the University of Alberta is leading the new effort. Too often cancer is detected at a late stage but when lung cancers are treated early, survival rates increase significantly. TMIC co-director David Wishart's team could transform lung cancer detection and save lives with…
READ MORE
April 29, 2021
Vancouver, British Columbia – (April 29, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment. The company’s aim is to obtain regulatory approval and clinical laboratory licenses to be fully operational in early 2022 and start offering […]
BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.